Tools

Back to the Top

Series

Michael J. Fox Foundation Launches Big PD Biomarker Study

A $40 million multicenter biomarker study for Parkinson disease progression is off and running, with enrollment underway at 10 of 18 sites in the U.S. and Europe. In design and operation, the Parkinson's Progression Markers Initiative (PPMI) follows in the footsteps of a similar study tracking brain imaging and fluid biomarkers in Alzheimer disease (see ARF ADNI series). PPMI will have a smaller cohort of 400 newly diagnosed PD patients and 200 controls, and focus heavily on cerebrospinal fluid biomarkers, while also collecting brain imaging, genetics, biologic, and clinical data. Read Esther Landhuis's series to learn all about this ambitious initiative.